摘要
目的:分析参芪扶正注射液联合经动脉化疗栓塞(TACE)治疗中晚期肝癌患者的效果和安全性。方法:选择2021年1月—2022年12月于广州市第一人民医院接受治疗的98例中晚期肝癌患者为研究对象,采用随机数表法均分为研究组和对照组,各49例。对照组仅予以TACE治疗,研究组在TACE的基础上予以静脉参芪扶正注射液联合治疗。比较两组的临床有效率、肝功能指标[谷丙转氨酶(ALT)、谷草转氨酶(AST)]、免疫学指标(CD3^(+)、CD4^(+)、CD8^(+)和CD4^(+)/CD8^(+))、不良反应发生率和生活质量。结果:研究组临床总有效率为79.59%,高于对照组的63.27%,差异有统计学意义(P<0.05)。术后2周,两组ALT、AST均低于术前1 d,且研究组上述指标均低于对照组,差异有统计学意义(P<0.05)。术后2周,研究组CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)高于术前1 d和对照组,而CD8^(+)水平低于术前1 d和对照组,差异有统计学意义(P<0.05)。研究组不良反应总发生率为30.61%,低于对照组的57.14%,差异有统计学意义(P<0.05)。研究组生活质量改善率为91.84%,高于对照组的65.31%,差异有统计学意义(P<0.05)。结论:参芪扶正注射液联合TACE治疗能够提高中晚期肝癌患者的临床有效率,保护患者的肝功能,减少患者TACE后不良反应,提高患者的免疫学水平和临床生活质量。
Objective:To analyze the efficacy and safety of Shenqi Fuzheng Injection combined with transarterial chemoembolization(TACE)in the treatment of patients with middle and advanced liver cancer.Method:A total of 98 patients with middle and advanced liver cancer who received treatment in Guangzhou First People's Hospital from January 2021 to December 2022 were selected as the study objects,and they were divided into study group and control group by random number table method,with 49 cases in each group.The control group was treated with TACE only,while the study group was treated with intravenous Shenqi Fuzheng Injection on the basis of TACE.The clinical effective rate,liver function indexes[alanine aminotransferase(ALT),aspartate aminotransferase(AST)],immunological indexes(CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)),incidence of adverse reactions and quality of life of the two groups were compared.Result:The total clinical effective rate of the study group was 79.59%,which was higher than 63.27%of the control group,the difference was statistically significant(P<0.05).At 2 weeks after surgery,ALT and AST in both groups were lower than those 1 d before surgery,and the above indexes in the study group were lower than those in the control group,the differences were statistically significant(P<0.05).At 2 weeks after surgery,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the study group were higher than those 1 d before surgery and control group,while CD8^(+)levels were lower than those 1 d before treatment and control group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the study group was 30.61%,which was lower than 57.14%in the control group,and the difference was statistically significant(P<0.05).The improvement rate of quality of life in the study group was 91.84%,which was higher than 65.31%in the control group,and the difference was statistically significant(P<0.05).Conclusion:Shenqi Fuzheng Injection combined with TACE can improve the clinical effective rate of patients with middle and advanced liver cancer,protect the liver function of patients,reduce the adverse reactions after TACE,and improve the immunological level and clinical quality of life.
作者
李西山
陈国东
LI Xishan;CHEN Guodong(Guangzhou First People's Hospital,Guangzhou 510180,China;不详)
出处
《中外医学研究》
2024年第2期105-108,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
基金
广州市卫生健康科技项目(20211A010005)。
关键词
肝癌
参芪扶正注射液
经动脉化疗栓塞
疗效
不良反应
Liver cancer
Shenqi Fuzheng Injection
Transarterial chemoembolization
Efficacy
Adverse reactions
作者简介
通信作者:陈国东。
